SHINGLES VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024 [DATE] [COMPANY NAME] [Company address] Report Description Shingles, also known as herpes zoster, is viral infection affecting the nerves. It is caused by the varicella zoster virus, the same virus that also cases chicken pox. The virus stays inactive for many years in the human body. Therefore, anyone who has had chicken pox in the past is at the risk of developing shingles. According to the Center for Disease Control and Prevention (CDC), there are an estimated one million cases of shingles every year in the Unites States. Moreover, CDC states that almost one in every three people in the United States will develop shingles in their lifetime. The risk of shingles increase as one gets older. However, cases are reported in people above 40 years. This is possibly due to weakening immune system on account of increased stress and inadequate intake of essential nutrients to keep immunity strong. Symptoms include skin rashes, nerve pain, vision loss, chills, upset stomach, muscle weakness, skin infection, and scarring. Treatment for shingles include antiviral medicines—acyclovir, valacyclovir, and famciclovir. These medicines help to shorten the length and alleviate the severity of illness. Further, analgesics may help relieve the pain. Ask For Table Of Content@ https://www.coherentmarketinsights.com/ongoing-insight/toc/73 Prevention of Shingles (Herpes Zoster) There is a safe and effective vaccine available for preventing shingles. The Zostavax vaccine licensed by Merck & Co's in 2006 is an effective vaccine against shingles. The vaccine is intended to be used in population over 50 years of age. The trials of the Zostavax vaccine demonstrated that the vaccine was 64% effective in people aged 60 to 69 years. The effectiveness reduces with increasing age i.e. to 41% for the 70-79 age group, and 18% for those 80 years of age and older. The vaccine was launched in the Indian market in February 2016, at half the price of the U.S. market. Zostavax, the only shingles vaccine in the market until now, recorded sales of USD 749 million in 2015. GlaxoSmithKline (GSK) is a global leader in vaccines market. It has filed for the U.S. approval of its shingles vaccine, Shingrix in October 2016. Shingrix has demonstrated better outcomes than the Zostavax in its clinical trials. The vaccines remained 90% efficacious in people over 70 years of age. The overall effectiveness of the vaccine is found to be 97%. Its higher effectiveness even among elder group of people will attract healthcare professionals to promote this vaccine. The impressive trail results would put Shingrix in a strong competitive position in the global market which is currently a monopoly situation. The company will be filing for regulatory approvals in the European and Canadian markets by the end of 2016, followed by Japan in 2017. It is estimated that the sales of Shingrix will reach USD 1 billion by 2021. Get More Details About This Report@ https://www.coherentmarketinsights.com/ongoinginsight/shingles-vaccines-market-73 Global Opportunity Awaiting Ahead Shingles is globally present with the risk increasing as the population ages. However, the high cost of vaccine is limiting the vaccination drive in emerging countries, where there is inadequate insurance coverage. The major concern among the healthcare experts is the reduction in postherpetic neuralgia from the shingles vaccine. Zostavax, have been successful to a certain extent in reducing postherpetic neuralgia due to the effect of the vaccine on reducing the risk of developing herpes zoster. Better outcomes of Shingrix will be a boon to the global shingles vaccines market. About Us COMPANY OVERVIEW Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future. Contact Us CORPORATE OFFICE: Coherent Market Insights 303, Astral Court,Above Reliance Fresh, Near Gaikwad Petrol Pump, Aundh, Pune – 411045, India Mail ID : [email protected]

There is a safe and effective vaccine available for preventing shingles. The Zostavax vaccine licensed by Merck & Co's in 2006 is an effective vaccine against shingles. The vaccine is intended to be used in population over 50 years of age.